首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Therapeutic Advances In Hematology

Therapeutic Advances In Hematology杂志,由SAGE PUBLICATIONS LTD出版,于2010年创刊,1 issue/year,出版语言English,ISSN:2040-6207,E-ISSN:2040-6215。

投稿咨询
Therapeutic Advances In Hematology
Therapeutic Advances In Hematology
Therapeutic Advances In Hematology
SCI SCIE

杂志介绍

JCR分区
Q2
中科院分区
2区
影响因子
2.8
CiteScore
5.3
期刊收录
SCI、SCIE

Therapeutic Advances In Hematology(中文译名:《血液学的治疗进展》),ISSN:2040-6207,EISSN:2040-6215,是SAGE PUBLICATIONS LTD出版的国际性学术期刊,创刊于2010年,以1 issue/year形式稳定发行,2026年总发文量约58篇。该刊采用OA开放访问,学科归属为HEMATOLOGY。该刊是医学、血液学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达2.8,2025年期刊CiteScore为5.3,2025年期刊自引率约3.6%,在中科院期刊分区体系中位列医学大类2区,在所属学科领域具备高学术影响力与国际认可度。Therapeutic Advances In Hematology长期聚焦医学、血液学及相关产业的技术应用前沿,平均审稿周期7 Weeks,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、血液学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USAItaly、CHINA MAINLAND、England、France、South Korea、Spain等为核心发文国家与地区;UNIVERSITY OF TEXAS SYSTEMMAYO CLINIC、HARVARD UNIVERSITY、ASSISTANCE PUBLIQUE HOPITAUX PARIS (APHP)、CHINESE ACADEMY OF MEDICAL SCIENCES - PEKING UNION MEDICAL COLLEGE、DANA-FARBER CANCER INSTITUTE、SEOUL ST. MARY'S HOSPITAL等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
HEMATOLOGY 血液学
2区
否 否

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
HEMATOLOGY 血液学
3区
否 否

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
HEMATOLOGY 血液学
3区
否 是

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:HEMATOLOGY SCIE Q2 42 / 103

59.7

学科:HEMATOLOGY SCIE Q2 42 / 103

59.71

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:HEMATOLOGY SCIE Q2 28 / 97

71.6

学科:HEMATOLOGY SCIE Q2 39 / 97

60.31


中国学者近期发文

1
A phase I/II study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia: final analysi

Author:Sawa, Masashi; Miyamoto, Toshihiro; Kim, Hee-Je; Hiramatsu, Yasushi; Cheong, June-Won; Ikezoe, Takayuki; Naoe, Tomoki; Akashi, Koichi; Morita, Satoshi; Kosako, Masanori; Shimura, Masaki; Terada, Wataru; Kadokura, Takeshi; Hill, Jason; Miyawaki, Shuichi; Gill, Stanley C.; Heinloth, Alexandra; Hasabou, Nahla

Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207261419953

2
Assessment of flonoltinib maleate versus ruxolitinib phosphate in intermediate- to high-risk myelofibrosis (FMF-02): study protocol for a multicenter, randomized, open-label phase IIB tria

Author:Yang, Linyu; Tan, Ke; Liang, Rui; Zhang, Wei; Wang, Yiqun; Chen, Lijuan

Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207261424845

3
The impact of clinical manifestations on the prognosis of diffuse large B-cell lymphom

Author:Wang, Siqian; Xu, Xi; Ma, Yongyong; Qian, Shanhu; Tang, Liyuan; Sun, Lan; Shen, Zhijian; Ye, Haige; Qian, Honglan; Jiang, Songfu; Zhou, Shujuan

Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207251410405

4
Early-onset de novo donor-specific anti-HLA antibodies may contribute to poor graft function following haploidentical transplantation for myelodysplastic syndrome: a rare case presentatio

Author:Huang, Xianbo; Wu, Xianhui; Wang, Shasha; Xu, Yu; Mei, Chen; Du, Fengwei; Ren, Yanling; Jin, Jie; Tong, Hongyan; Qian, Jiejing

Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207261417496

5
Real-world clinical outcomes of autologous stem cell transplantation in Chinese patients with newly diagnosed multiple myeloma: a systematic literature revie

Author:You, Jiawen; Zhang, Yuanyuan; Meng, Yuan; Zhao, Yiming; Huang, Huiqing; Chen, Wendong; Meng, Jianbo

Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207261417132

6
Endothelial dysfunction and cardiac damage indicators in patients with β-thalassemia major under iron-chelation therap

Author:Al-Sanabra, Ola M.; Abbas, Manal A.; Haza, Wafa J.; Hazaa, Abeer A

Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207261417140

7
Comparing two different doses of anti-thymocyte globulin in allogeneic hematopoietic stem cell transplantation for transfusion-dependent thalassemia: an open-label, randomized clinical tria

Author:Huang, Qiulin; Liu, Rongrong; Zheng, Baoshi; Liu, Lianjin; Xiao, Hongwen; Wu, Meiqing; Shi, Lingling; Yang, Gaohui; Wei, Zhenbin; Zhou, Qi; Chen, Yinghua; Liu, Yanye; Fan, Jing; Zhou, Xuemei; Li, Ruolin; Zeng, Zhiyu; Zhang, Zhongming; Lai, Yongrong

Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207261416816

8
Recombinant von Willebrand factor for von Willebrand disease: mechanism of action and clinical applicatio

Author:Hua, Zhengjie; Miao, Wenjuan; Zhang, Ping; Yang, Renchi

Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207261419941

9
Efficacy and safety of chimeric antigen receptor T-cell therapy in relapsed/refractory large B-cell lymphoma: a systematic review and meta-analysi

Author:Li, Qiang; Xu, Shenghua; Zhong, Yun; Rao, Peng; Huang, Hui; Huang, Yan

Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207251407511

10
The efficacy and safety of asciminib treatment in patients with chronic myeloid leukemia as a second-line or beyond second-line treatment: a systematic review and meta-analysi

Author:Fan, Zixin; Xie, Jiayi; Su, Pinying; Tai, Jingye; Feng, Weiyi; Xu, Rui; Ouyang, Yun

Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2025; Vol. 16, Issue , pp. -. DOI: 10.1177/20406207251342203


在线咨询

Therapeutic Advances In Hematology

国际简称:THER ADV HEMATOL参考译名:血液学的治疗进展

年发文量:58 CiteScore:5.3 是否预警:否 Gold OA文章占比:100.00% 研究类文章占比:84.48%

杂志社联系方式:1 OLIVERS YARD, 55 CITY ROAD, LONDON, ENGLAND, EC1Y 1SP

Therapeutic Advances In Hematology